Key clinical point: Oral methotrexate achieved significant reductions in knee osteoarthritis pain, stiffness, and functional impairment.
Major finding: The standard effect size for methotrexate in terms of pain reduction was 0.36, considered to be moderate.
Study details: This multicenter, randomized, double-blind, placebo-controlled clinical trial included 134 patients evaluated at 6 months.
Disclosures: The presenter reported having no financial conflicts regarding the PROMOTE trial, which was funded by the U.K. National Institute for Health Research and Versus Arthritis.
Conaghan PG et al. OARSI 2019, Abstract 86.